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Abstract
Backround: Hepatic radiation toxicity restricts irradiation of liver malignancies. Better knowledge of hepatic
tolerance dose is favourable to gain higher safety and to optimize radiation regimes in radiotherapy of the liver. In
this study we sought to determine the hepatic tolerance dose to small volume single fraction high dose rate
irradiation.
Materials and methods: 23 liver metastases were treated by CT-guided interstitial brachytherapy. MRI was
performed 3 days, 6, 12 and 24 weeks after therapy. MR-sequences were conducted with T1-w GRE enhanced by
hepatocyte-targeted Gd-EOB-DTPA. All MRI data sets were merged with 3D-dosimetry data. The reviewer indicated
the border of hypointensity on T1-w images (loss of hepatocyte function) or hyperintensity on T2-w images
(edema). Based on the volume data, a dose-volume-histogram was calculated. We estimated the threshold dose for
edema or function loss as the D90, i.e. the dose achieved in at least 90% of the pseudolesion volume.
Results: At six weeks post brachytherapy, the hepatocyte function loss reached its maximum extending to the
former 9.4Gy isosurface in median (i.e., ≥9.4Gy dose exposure led to hepatocyte dysfunction). After 12 and 24
weeks, the dysfunctional volume had decreased significantly to a median of 11.4Gy and 14Gy isosurface,
respectively, as a result of repair mechanisms. Development of edema was maximal at six weeks post
brachytherapy (9.2Gy isosurface in median), and regeneration led to a decrease of the isosurface to a median of
11.3Gy between 6 and 12 weeks. The dose exposure leading to hepatocyte dysfunction was not significantly
different from the dose provoking edema.
Conclusion: Hepatic injury peaked 6 weeks after small volume irradiation. Ongoing repair was observed up to 6
months. Individual dose sensitivity may differ as demonstrated by a relatively high standard deviation of threshold
values in our own as well as all other published data.
Backround
Irradiation of liver malignancies has evolved as an effec-
tive treatment alternative to liver surgery in selected
patients. Both external radiotherapy as well as image
guided brachytherapy have been described in the litera-
ture with promising results [1-4]. One of the few limit-
ing factors is the tolerance dose of the surrounding liver
parenchyma.
Literature of quantitative in vivo data of the hepatic
tolerance to irradiation is limited [5-8]. However, such
knowledge is essential for the treatment strategy in
patients with multiple or large tumors or in situations
with a small parenchymal reserve after liver resection.
Previous studies on the tolerance dose of the liver are
mainly based on fractionated large volume liver irradia-
tion with the clinical endpoint of radiation induced liver
disease (RILD). This status may occur if more than 30 -
55 Gy are applied, depending on the irradiated liver
volume [6,7,9-14]. These doses lead to a decline of the
total organ function causing clinical symptoms.
* Correspondence: max.seidensticker@med.ovgu.de
1Klinik für Radiologie und Nuklearmedizin, Universitätsklinikum Magdeburg,
Otto-von-Guericke-Universität Magdeburg, Germany
Full list of author information is available at the end of the article
Seidensticker et al. Radiation Oncology 2011, 6:40
http://www.ro-journal.com/content/6/1/40
© 2011 Seidensticker et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.However, this does not necessarily reflect the inherent
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Computed tomography (CT)-guided brachytherapy of
liver malignancies utilizes CT fluoroscopy for catheter
positioning and three dimensional (3D) CT-data sets for
dose planning. During follow up after irradiation, mag-
netic resonance imaging (MRI) may be used as a sensi-
tive method to detect edema as well as liver function
loss by employing hepatocyte-directed contrast agents.
By applying image fusion of follow up MRI with the
treatment planning CT, the isodoses calculated for inter-
stitial irradiation can be displayed in the MRI scans,
indicating the exact dose distribution at any given time
point during follow up. In a precursor study, we utilized
this approach along with the hepatocyte directed con-
trast agent Gadobenate dimeglumine (Gd-BOPTA). We
determined a median threshold dose of 9.9 Gy after six
w e e k sa st h em i n i m a lt o l e r ance dose of small volume
liver parenchyma to single fraction high dose rate
(HDR) brachytherapy over time [8].
However, Gd-BOPTA displays only a small biliary
excretion of only 6%. In contrast, Gadolinium ethoxy-
benzyl diethylenetriamine-pentaacetate (Gd-EOB-
DTPA), a second generation hepatocyte directed con-
trast agent, has shown vast improvements over Gd-
BOPTA in liver contrast through biliary excretion rates
of >50% [15-18]. By employing Gd-EOB-DTPA in the
study described herein we sought to determine the
hepatic tolerance dose to small volume single fraction
high dose irradiation as primary endpoint. As secondary
endpoints we searched for factors of influence on the
threshold dose (history of chemotherapy, irradiated
volume etc.) and we intended to gain a more accurate
assessment of dose thresholds specifically in light of the
relatively high standard deviation in the precursor study
employing Gd-BOPTA. As with Gd-BOPTA, surrogate
for local liver function was a diminished uptake of the
contrast agent in liver parenchyma, and image fusion
with dosimetry data determined the respective threshold
doses.
Material and methods
Patient identification
Twenty-three patients were included in this study. All
patients were scheduled to receive a CT guided HDR
single fraction brachytherapy of one liver malignancy
each. Follow-up MRI employed Gd-EOB-DTPA. The
study was approved by the institutional ethics
committee.
The patient population comprised of 12 men and 11
women. The mean age was 66 years (30-84 years). All
patients demonstrated a Karnofsky score greater than
80%. All liver tumors were metastastic, and liver cirrho-
sis was exclusion criteria. The primary tumors were:
10 colorectal, 8 breast, 3 renal cell, 1 gastric and 1 non
small cell lung cancer (Table 1).
Eligibility criteria
In addition to patients with clinical signs of liver cirrho-
sis we excluded patients who had previously undergone
radiotherapy of the liver. To avoid confounding radio-
sensitizing effects or toxicities, systemic chemotherapy
was paused for at least 14 days prior and post bra-
chytherapy (Table 1).
Interventional technique and follow up
The technique of CT-guided brachytherapy has been
described in detail elsewhere [3,4]. In brief, placement of
the brachytherapy applicators was performed under CT
fluoroscopy. For treatment planning purposes, a spiral
CT of the liver (slice thickness: 5 mm; increment: 5
mm) enhanced by intravenous administration of iodide
contrast media (100 ml Ultravist 370, Bayer Schering
Pharma, Berlin, Germany, flow: 1 ml/s; start delay: 80s)
was acquired after positioning of the brachytherapy
catheters in the tumor. A median of three catheters was
used in our patients (range: 1 - 7 catheters).
The planning CT data set was digitally transferred to
the treatment planning unit (BrachyVision
®,V a r i a n
Medical Systems, Charlottesville, VA, USA). A radiolo-
gist defined the Clinical Target Volume (CTV) in the
planning CT data set (Figure 1b). An one day prior to
treatment obtained MRI of the liver was taken visually
into account to avoid underestimation of the tumor size.
To fulfill dosimetry planning in a timely manner, no
registration of pre-treatment MRI with planning CT was
performed due to patient safety and patient comfort.
Based on literature and on own, yet unpublished data,
the prescribed minimal dose inside the CTV was 15 to
20 Gy [4]. The true D100 applied was 14.3 to 21.2
(median 20Gy). The CTV ranged from 0.8 ml to 340.4
ml (median 20.5 ml), the volume (tumor plus liver par-
enchyma) which was exposed to more than 10 Gy ran-
ged from 14.7 - 689 ml (median 137.7 ml) (Table 1).
The high dose rate afterloading system employed a
192Iridium source of 10Ci (Gammamed
®, Varian medical
systems, Charlottesville, VA, USA). The source diameter
was < 1 mm. Dwell positions were located every 5 mm.
Dwell times were corrected automatically according to
the actual source strength. The median duration of irra-
diation was 1154 seconds (range: 250 to 3762 seconds).
The calibration factor used to compensate for the
decay of the
192Iridium source ranged from 0.88 to 1.65
(median 1.36) relative to 10Ci.
Baseline MRI (Gyroscan NT
® 1.5T, Philips, Best, The
Netherlands) was obtained in all patients one day prior
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days, 6, 12 and 24 weeks after treatment. The MRI pro-
tocol consisted of the following sequences: T2-weighted
(T2-w) ultrafast spinecho (UTSE) (time to echo (TE)/
time to repetition (TR) 90/2100 ms) with and without
fat suppression, T1-weighted (T1-w) gradient echo
(GRE) (TE/TR 5/30 ms, flip angle 30°) pre-contrast, 20s,
60s and 120s post intravenous administration of 0.025
mmol/kg bodyweight Gd-EOB-DTPA (Primovist
®, Bayer
Schering Pharma, Berlin, Germany), and 20 minutes
post injection of intravenous Gd-EOB-DTPA. The slice
thickness was 5 mm (T1-w) and 8 mm (T2-w) acquired
in interleafed mode with no gap applied.
Gd-EOB-DTPA
We used the diminished uptake of the hepatocyte speci-
fic contrast agent Gd-EOB-DTPA as a surrogate marker
for the functioning state of the liver parenchyma. Gd-
Table 1 Patient identification and previous cancer therapies
Patient Age
-yr
Primary
Tumor
site
Treatment date
(months after
first diagnosis)
Liver
Volume
-ccm
CTV
-ccm
With ≥10 Gy
irradiated Liver
Volume -ccm
Chemotherapy prior
to brachytherapy
Chemotherapy
during follow-
up
Liver resection or
local treatment
prior to
brachytherapy
1 84 Colon 79 1063 66.7 249.5 n/a none Right
hemihepatectomy,
RFA
2 69 Gastric 16 1720 340.4 689 CAP+DOC, CAP none none
3 66 Lung 10 2135 30.6 205 none GEM RFA
4 66 Colon 13 1296 3.64 19 FOLFOX none none
5 66 Breast 83 1206 2.7 79.5 TAM, END+EPI+5FU/FA,
EXE
EXE none
6 63 Breast 18 1301 41.5 277.7 VP 16+JM8, DOC GEM, DOC+CAP none
7 72 Colon 30 1499 23.1 141 5FU/FA, FOLFOX none Wedge resection S4
8 30 Breast 12 1334 9.2 90.6 DOC+EPI, TAM+LEU,
VIN+ Anti-Her-2/neu,
5FU/FA
CAP none
9 61 Breast n/a 1406 15.1 91.3 none none Wedge resection S4
10 70 Colon 14 2672 20.5 181 5FU/FA none none
11 58 Colon 49 1531 36.4 236 5FU/FA, FOLFIRI,
FOLFOX
none none
12 69 Colon 43 1610 100.7 381.6 FOLFIRI, FOLFOX, 5FU/
FA, Anti-EGFR +CPT11
Anti-EGFR
+CPT11
none
13 61 Colon n/a 1350 123.6 327.6 FOLFOX+Anti-VEGF,
5FU/FA,
FOLFOX Right
hemihepatectomy,
RFA
14 72 Renal n/a 1170 1.7 49.4 none none Wedge resection, RFA
15 55 Colon 56 1484 58.5 370 FOLFIRI, FOLFOX none Right
hemihepatectomy
16 62 Colon 20 1247 4.9 104.5 FOLFOX none none
17 56 Renal 6 822 30.5 137.7 none SOR none
18 55 Colon 22 1170 7.3 145 CAP+L-OHP, CAP+L-
OHP+ Anti-VEGF
none Right
hemihepatectomy
19 69 Breast 34 1073 10.1 60.1 EPI+DOC, Anti-Her-2/
neu +CAP+VIN, SDX
105, DOC
none none
20 53 Breast 125 1054 0.8 22.2 VP 16+CAR, DOC+ADR,
TAM, EXE, LET, 5FU/FA
+CTX+EPI, FUL, GEM
none none
21 52 Breast 16 1650 7.1 102 VP 16+JM8, LET CAP none
22 76 Renal 156 930 2.9 14.7 none none Wedge resection, RFA
23 77 Breast 80 1503 28.9 100.7 CAP none none
Abbreviations: Bendamustine (SDX 105), Bevacizumab (Anti-VEGF), Capecitabine (CAP), Carboplatin (JM8), Cetuximab (Anti-EGFR), Cyclophosphamide (CTX),
Docetaxel (DOC), Doxorubicin (ADR), Endoxane (END), Epirubicin (EPI), Etoposide (VP 16), Exemestan (EXE), 5-Fluorouracil (5FU), Folic acid (FA), 5-Fluorouracil/Folic
acid +Irinotecan (FOLFIRI), 5-Fluorouracil/Folic acid +Oxaliplatin (FOLFOX), Fulvestrant (FUL), Gemcitabine (GEM), Irinotecan (CPT 11), Letrozole (LET), Leuprorelin
(LEU), Oxaliplatin (L-OHP), Sorafenib (SOR), Tamoxifen (TAM), Trastuzumab (Anti-Her-2/neu), Vinorelbine (VIN).
Combined applications are marked by +. Comma marks indicate sequential chemotherapeutic regimens.
Clinical Target Volume (CTV), Radiofrequency Ablation (RFA)
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Page 3 of 13EOB-DTPA is a newly developed water soluble MR con-
trast agent containing a lipophilic moiety. Like other
gadolinium contrast media, the contrast function is basi-
cally determined by the paramagnetic gadolinium ion
leading to a high T1 relaxivity. Unlike common MRI
contrast agents (e.g. Gd-DTPA), Gd-EOB-DTPA is dis-
tributed not only to the extracellular fluid space, but
taken up by the organic anion transporting polypeptide
(OATP) of the hepatocytes. It is excreted via the canali-
cular multispecific organic anion transporter (cMOAT/
mrp2) following a linear, concentration dependent
mechanism [19-22]. Animal studies have shown a biliary
excretion rate of 63-80% and 32-34% in rats and
simians, respectively. Biodistribution studies in humans
reveal a dose independent biliary (41.6-51.2%) and renal
(43.1-53.2%) elimination and an enterohepatic recircula-
tion of approximately 4%. Enhancement during the dis-
tribution phase of the contrast agent mainly depends on
the vascularity, while enhancement on delayed images
20 minutes after administration is characterized by the
selective uptake of the contrast agent by the hepato-
cytes. Non-hepatic tissue (e.g. liver metastases) shows
no contrast enhancement on delayed images
[15,17,21,23-26] (Figure 1a + c). The signal intensity of
 
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Figure 1 Illustration of CT guided brachytherapy and post interventional hepatic dysfunction in MRI.( a )B a s e l i n eM R I .T 1 - wG R E2 0
minutes post i.v. application of Gd-EOB-DTPA. Colorectal liver metastasis in segment 6/7 (white arrow). (b) Contrast-enhanced computed
tomography (CT) after CT-guided positioning of one brachytherapy catheter (truncated, black arrowhead) in the metastasis. The red line
resembles the 15Gy isodose. (c) MRI 6 weeks after treatment. T1-w GRE 20 minutes post i.v. application of Gd-EOB-DTPA. Signal void around the
tumor indicates hepatocyte dysfunction of liver parenchyma (black arrow). No evidence of tumor regrowth in (d): T1-w GRE dynamic scan 60s
after application of the contrast dye shows shrinkage resulting from tumor necrosis after irradiation (black arrow).
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the functioning state of the according hepatocytes with
a decreased signal intensity in dysfunctional liver par-
enchyma [27]. Thus a MRI based volumetric assessment
of liver parenchyma damage is possible.
Image registration
Quantitative analysis of hepatocellular dysfunction and
edema in areas exposed to focal high dose rate bra-
chytherapy was performed using T1-w GRE 20 minutes
post intravenous administration of Gd-EOB-DTPA and
T2-w UTSE with fat suppression, respectively. Follow-
up imaging was performed at four follow-up time-points
(3 days, 6, 12 and 24 weeks after brachytherapy) leading
to a total number of 92 MRI scans in 23 patients.
For image fusion of the follow-up MRI scans with the
according treatment plan (based on the planning CT
data set), MRI data was transferred to the treatment
planning system. BrachyVision
® offers an isoscalar local
semi-automated point based 3D-3D image registration.
Match points were defined on corresponding landmarks
such as branches of the portal vein to enable fusion of
MR and planning CT/dosimetry data. Landmarks were
restricted to liver structures.
A linear interpolation was performed automatically by
BrachyVision
® to match the varying slice thicknesses of
T2-w MRI (8 mm) and CT (5 mm). As a result of this
procedure, BrachyVision
® simultaneously displayed the
treatment plan as well as the anatomical structures of
the MRI scan (Figure 2a -c). The absolute registration
error was always less than 5 mm. A retrospective regis-
tration of pre-treatment MRI with planning CT/dosime-
try to obtain the CTV as basline in MRI was deemed
inappropriate due to a possible additional registration
error. As already stated the tumor extent in pre treat-
ment MRI was respected in dosimetry planning.
Quantitative analysis
On all of the T1-w late Gd-EOB-DTPA as well as the
T2-w enhanced images an experienced GI Radiologist
digitally outlined the border of hypointensity on T1-w
images (loss of hepatocyte function as displayed by
diminished Gd-EOB-DTPA uptake) or hyperintensity on
T2-w images (edema) around the irradiated liver tumor
(referred to as “pseudolesion (including the irradiated
tumor)” in the following). Pre-existing peritumoral
changes could be excluded on the pre treatment MRI.
Based on the total 3D data set of these volumes, the
Brachyvision
® software calculated a dose-volume histo-
gram. As a result, we determined the percentage of each
pseudolesion receiving a specific dose. We specified the
threshold dose for either edema or function loss as the
D90, i.e. the dose achieved in at least 90% of the pseudo-
lesion volume (Figure 3).
As an additional descriptor, we determined the
volume of each pseudolesion in relation to the former
intrahepatic 10Gy isodose volume. This additional
volumetric approach was performed as an independent
verification of the previously described methodology.
Laboratory analysis
One day prior to the intervention and during follow up
we assessed the following laboratory parameters: biliru-
bin, aspartate aminotransferase, alanine aminotransfer-
ase, alkaline phosphatase, albumin, international
normalized ratio, and cholinesterase. Laboratory para-
meters were graded according to the ‘Common Termi-
nology Criteria for Adverse Events’ (CTCAE version
4.02, National Cancer Institute, USA).
No patient presented evidence of liver function degra-
dation prior to therapy.
Factors of influence
Following factors were recorded and tested for influence
on the minimal dose provoking edema or hepatocyte
function loss (i.e. the dose at 6 weeks): patient age, the
liver volume, the clinical target volume, the liver volume
which was exposed with more than 5Gy or 10Gy, the
source factor, the irradiation time, the number of cathe-
ters applied, history of chemotherapy.
Statistical analysis
Results of continuous data are displayed as medians and
ranges and/or lower and upper quartile, results of fre-
quency data as counts and percentages.
For two-group comparisons of the medians two-sided
Wilcoxon rank sum tests were used. Correlations were
evaluated using a two sided Pearson correlation test.
A p < 0.05 was considered to be statistically significant.
For statistical analysis the software ‘Statistical Package
for the Social Sciences’ (IBM SPSS, Version 17.0, Som-
ers, NY, USA) was used.
Results
The registration error of the landmarks after image
fusion of the planning CT to the follow-up MRI was as
follows: in median 0.95 mm (0.53-1.5), 1.82 mm (0.22-
2.91), 1.79 mm (0.81-2.91) and 2.04 mm (0.85-5) for the
T1 weighted sequences at 3 days, 6, 12 and 24 weeks,
respectively. For the T2 weighted images, the registra-
tion error was in median 0.98 mm (0.59-1.3), 1.75 mm
(0.79-3.65), 1.89 mm (0.81-3.89) and 1.98 mm (0.98-
3.53), respectively.
Figure 4a + b display the development of hepatocyte
dysfunction or hepatic edema in correlation to the iso-
dose distribution. Three days after brachytherapy, the
D90 for hepatocyte function loss reached a median of
19.5Gy (7.4-53.1, Q25: 16.9, Q75: 21.1), i.e. doses
Seidensticker et al. Radiation Oncology 2011, 6:40
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Page 5 of 13≥19.5Gy provoked a state of hepatocyte dysfunction. At
six weeks, the isosurface had increased significantly to a
median of 9.4 Gy (6.4-16.6, Q25:8 . 5 ,Q 75:1 1 . 7 ;p<
0.001), i.e. protracted toxic effects lowered the threshold
dose for hepatic dysfunction to 9.4Gy. Between 6 and 12
weeks, the dysfunctional volume had decreased
significantly to a median of 11.4Gy (7.8-20.2, Q25:9 ,
Q75: 14.5; p = 0.002). After 24 weeks, the isosurface
decreased further to a median of 14 Gy (7.9-24.7, Q25:
10.5, Q75: 17.6; p = 0.002).
Between three days and 6 weeks, the extension of the
edema increased significantly from the 19.1Gy (7.8-33.8,

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Figure 2 Image fusion of planning CT/dosimetry and follow-up MRI. (a) Contrast-enhanced CT after CT-guided positioning of 5
brachytherapy catheters in a colorectal metastasis (one catheter is labeled with a black arrowhead, the other catheter positions in cranial or
caudal planes are indicated by green arrows). Isodoses lines the CTV (blue circle) after dosimetry with BrachyVision
® (b + c). MRI 3 months after
brachytherapy: T1-w gradient echo 20 minutes post i.v. application of Gd-EOB DTPA (b) and T2-w UTSE FS (c) showing image fusion with the
treatment planning CT.
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Page 6 of 13Q25: 12.3, Q75: 22.7) isosurface to 9.2Gy at median (5.9-
17.4, Q25:6 . 8 ,Q 75: 10.9; p < 0.001). After this peak a sig-
nificant decrease occurred between 6 and 12 weeks (med-
ian 11.3Gy, 7.4-18.4, Q25:9 . 3 ,Q 75: 13.1; p = 0.002). After
24 weeks, the edematous tissue isosurface shrank to a
median of 11.8 Gy (7.9-24.3, Q25:9 . 3 ,Q 75: 14.8; p = 0.018).
At three days post brachytherapy, the minimal dose
leading to edema tended to be less compared to the
dose provoking focal hepatocyte function loss (p =
0.055). No differences between the doses provoking
focal hepatic dysfunction or edema were noted at 6, 12
and 24 weeks (p = 0.158, 0.212 and 0.128, respectively).
Figure 5a + b illustrate the development of the volume
of focal hepatocyte function loss or edema post bra-
chytherapy in correlation to the liver volume which was
exposed with more than 10Gy. The relative volume of
hepatocyte function loss increased significantly between
three days and 6 weeks (p < 0.001) with an extend to
81% of the 10Gy volume in median after 6 weeks (Q25:
61%, Q75: 100%). After 12 weeks, the decline of the
volume with hepatocyte function loss was significant
compared to 6 weeks (58%, Q25: 43%, Q75:7 6 % ;p<
0.001), and again after 24 weeks when compared to 12
weeks (36%, Q25:2 7 % ,Q 75: 51%; p < 0.001). Between
three days and 6 weeks, edema volume increased signifi-
cantly (6 weeks: 91%, Q25:6 3 ,Q 75: 116%; p < 0.001).
From week 6 to week 12, edema volume shrank signifi-
cantly (68%, Q25:5 4 % ,Q 75: 91%; p = 0.001) and contin-
ued to week 24 with a significant decrease (48%, Q25:
31%, Q75: 60%; p < 0.001). At all time points the size of
the edema volume surmounted the size of the volume
of hepatocyte dysfunction in relation to the 10 Gy
volume (p < 0.05).
We found no statistical correlation between the mini-
mal dose provoking edema or hepatocyte function loss
(i.e. the dose at 6 weeks) and: patient age, the liver
volume, the clinical target volume, the liver volume
which was exposed with more than 5Gy or 10Gy, the
source factor, the irradiation time, the number of cathe-
ters applied, or a history of chemotherapy.
No patient included in this study demonstrated a
severe impairment of liver function as measured by the
above named laboratory parameters before CT guided
brachytherapy. No severe acute or late toxicity were
observed after CT guided brachytherapy. Liver function
tests graded according to the ‘common terminology cri-
teria for adverse events’ (CTCAE) version 4.02 never
exceeded grade 2 toxicities during follow up.
Discussion
Quantitative data on the radiation threshold dose of hepa-
tic tissue is scarce compared to other late-responding
Figure 3 Dose-Volume-Histogram of nonfunctioning liver volume. Dose volume histogram of nonfunctioning liver volume in a patient 3
months after HDR brachytherapy. (D90: the dose applied to at least 90% of the volume, in this case 12.92 Gy.)
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Page 7 of 13tissues. In this study we used regional uptake of the hepa-
tocyte specific MRI contrast media Gd-EOB-DTPA as a
surrogate parameter for hepatic function after HDR irra-
diation of small liver volumes. Thus we were able to deter-
mine the hepatocyte tolerance dose in vivo. Small volumes
of hepatic parenchyma irradiated with more than 9.4Gy
revealed a non functioning state after six weeks. After six
months, recovery of hepatic parenchyma led to a threshold
dose of 14 Gy for hepatic dysfunction.
The histological appearance of radiation induced liver
disease indicates that endothelial injury and subsequent
obstruction of centrilobular venules and sinusoids are
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Figure 4 Boxplot of threshold doses of hepatocyte function loss and edema over time. (a) Hepatocyte function loss over time relative to
dose exposition. (b) Development of the according edema.
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Page 8 of 13the key events in the pathogenesis of radiation injury of
the liver. Larger veins are frequently spared [7,12,13,28].
The pathological lesion resembles veno-occlusive dis-
ease, frequently seen after total body irradiation in
induction therapy prior to bone marrow transplantation
[29-31]. This initial injury is followed by a wide, edema-
tous subendothelial zone, resembling deposits of fibrin-
related aggregates and fragmented red cells in the
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Figure 5 Boxplot of volume of hepatocyte function loss and edema over time. Development of hepatic function loss (a) and edema (b)
around the irradiated tumor relative to the 10 Gy isodose volume (liver parenchyma only).
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Page 9 of 13subendothelial zone. Early deposition of fibrinogen is
frequently found without platelet accumulation. These
aggregates, as well as the intramural entrapment of fluid
and cellular debris, progressively occlude the hepatic
venous outflow by intraluminal sinusoidal fibrous mate-
rial, subendothelial collagen fibers and foamy cells
[7,13,28] (Figure 6). Experimental studies on hepatic
radiation injury support the theory that the endothelial
lining of venules and sinusoids is far more sensitive to
radiation than hepatocytes [32-34].
However, changes of uptake of a hepatocyte specific
contrast media illuminate the final path of the radiation
injury, i.e. these changes visualize areas of a dysfunc-
tional hepatic system, not necessarily individual hepato-
cyte dysfunction [27]. The model does not differentiate
whether parenchymal (hepatocytes) or non-parenchymal
cells (endothelial-, Kupffer- and Ito-cells) play the key
role in the development of focal hepatic dysfunction.
Hence, our model must be interpreted as the reaction of
a liver functioning unit to irradiation.
Therapeutic irradiation of liver malignancies is
restricted by hepatic tolerance with the clinical endpoint
liver function loss. In total or large volume irradiation
of the liver, major complications such as RILD have fre-
quently been described [6,7,10,11]. However, the parallel
functional structure of the liver may cover a loss of
extensive liver volume without clinical symptoms such
as after hepatectomy. A comparison between data of
total or large volume liver irradiation using the clinical
endpoint RILD or liver failure has to be differentiated
from small volume irradiation as executed in our study.
CT-guided brachytherapy as well as stereotactic irradia-
tion of liver malignancies are locally circumscribed
radiotherapies designed to spare healthy liver parench-
yma. In a clinical setting, a relatively small rim of liver
parenchyma around the CTV is exposed to high irradia-
tion doses. This limited loss of functioning hepatic tis-
sue is generally tolerated well without any impairment
of the whole organ function as seen by unchanged liver
function parameters during follow-up [35]. However,
Figure 6 Histological specimen: liver tissue after radiation exposure. Liver biopsy in an area exposed to approximately 20 Gy two months
earlier. Severe sinusoidal congestion with atrophy of hepatocytes (A) and increased perisinusoidal reticulin deposition (B). Hematoxylin-eosin (A)
and Gomori’s silver stain (B), original magnification: x200. Biopsy was taken to rule out local recurrence.
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Page 10 of 13caution should be exercised if the total volume of unex-
posed liver is small such as
￿ in patients scheduled for synchronous multifocal
irradiation of liver malignancies because of overlap-
ping isodoses of the single lesions.
￿ in patients scheduled for irradiation of a large
tumor volume in small livers.
￿ in patients scheduled for irradiation with a history
of partial liver resection because of a potentially
small residual parenchymal volume.
￿ In patients with chronic and/or degenerative liver
diseases (such as cirrhosis).
An increase of the incidence of clinical RILD has been
observed in total liver irradiation when doses 30-55Gy
are delivered applying conventional fractionation
schemes [6,7,10-14,28]. These fractionated tolerance
doses translate into single-fraction doses of 11.25 up to
14Gy, respectively, according to the linear-quadratic
model and an assumed a/b of 3Gy for liver tissue [11].
These threshold values correspond well to our own data
on focal liver dysfunction after single fraction small
volume irradiation and correspond well to observed
clinical significant hepatic injury after doses as low as
10Gy in patients undergoing a single fractioned total
body or abdominal irradiation and chemotherapy prior
to bone marrow transplantation [29,30,36]. However, an
unequal dose rate of the different approaches has to be
considered.
The reaction of small liver volumes to irradiation has
also been studied by other groups. Herfarth et al. exam-
ined hepatic tolerance after applying stereotactic single-
fraction irradiation to liver malignancies with data
derived from follow-up contrast-enhanced CT. The
authors observed a focal reaction at a dose minimum of
mean 13.7Gy (range 8.9 -19.2Gy) [5]. In principle, con-
trast enhanced CT will most likely demonstrate the
venous outflow occlusion after radiation exposure. This
approach visualizes the underlying pathophysiological
change provoking focal liver function degradation. Con-
sequently, the results of this workgroup match well with
the data derived from our model applying hepatocyte
directed contrast agent in MRI, visualizing the effect of
venous outflow occlusion with distraction of a liver
function unit as described above. It remains question-
able whether the higher standard deviation of their
results may be explained by a smaller sensitivity of the
CT model as compared to MRI [5,8].
In the present study we not only sought to add further
data on hepatic dose tolerance, but to improve the study
concept applied previously that had used the first gen-
eration hepatocyte-directed contrast agent Gd-BOPTA
[8]. While the pharmacodynamics of Gd-BOPTA are
similar to those of Gd-EOB-DTPA, the pharmacoki-
netics differ significantly. The biliary excretion rate of
Gd-BOPTA is just 0.6 to 4% compared to 41.6 to 51.2%
in Gd-EOB-DTPA [15-18]. This results in a higher sig-
nal-to-noise-ratio in Gd-EOB-DTPA and consequently
to a better demarcation of liver lesions and non-func-
tional parenchyma. The results presented in this study
determining the threshold dose of hepatocytes support
the data from the precursor study using Gd-BOPTA [8].
Apart from the different hepatocyte specific contrast
agent used (Gd-BOPTA vs. Gd EOB DTPA) in MRI fol-
low up, the design of these two studies was similar. The
minimal tolerance dose to high dose irradiation in the
precursor study was determined with 9.5Gy in median
(6-14.5, Q25:8 ,Q 75: 12) after six weeks (n = 25), com-
pared to 9.4Gy in median (6.4-16.6, Q25:8 . 5 ,Q 75:1 1 . 7 )
in the present study. Both studies showed a strong
recuperation of dysfunctional liver parenchyma after six
months with a residual non-functioning liver parench-
yma in areas irradiated with formerly more than 15.2Gy
in median (7.5-23, Q25:1 2 ,Q 75: 18) and 14 Gy in med-
ian (7.9-24.7, Q25: 10.5, Q75: 17.6) at present [8].
However, we did not reach our goal to decrease the
relatively high variation from the precursor study
employing Gd-BOPTA, despite the superior imaging
properties of Gd-EOB-DTPA. We attribute this failure
to the fact that individual differences in hepatic dose
tolerance do not preferably reflect flaws of the imaging
model, but rather unknown factors of individual predis-
position. In other words, data derived from different
models (including CT or MR imaging) consistently
shows deviations of individual hepatic dose tolerance to
small volume single fraction irradiation.
Conclusion
In summary, our study supports previous data on hepa-
tic tolerance doses after single fraction, high dose rate
small volume irradiation. We conclude that the thresh-
old dose to induce a focal loss of liver function is about
10 Gy after 6 weeks. We confirmed previously observed
strong recuperation with a threshold dose of 14 Gy after
6 months. These results should be considered specifi-
cally in cases where more than one liver lesion shall be
irradiated, or in patients with a history of focal liver
irradiation. Further investigation is warranted to assess
the correlation between deminished uptake of Gd-EOB-
DTPA in the affected liver volume and clinical symp-
toms as liver function degradation before routine use of
Gd-EOB-DTPA can be recommended in this matter.
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